Targeted Therapy (Investigational Antibody / ADC)
48 molecules in this therapeutic area. Open any product for its details, or send an inquiry directly.
Targeted Therapy (Investigational Antibody / ADC) (48)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Nogapendekin Alfa Inbakicept |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Nogapendekin Alfa Inbakicept
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Otlertuzumab |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Otlertuzumab
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Petosemtamab |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Petosemtamab
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Pinatuzumab Vedotin |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Pinatuzumab Vedotin
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Raludotatug Deruxtecan |
Anti-CDH6 ADC, Topoisomerase I Inhibitor Payload | Solid Tumour | ||
|
Molecule
Raludotatug Deruxtecan
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-CDH6 ADC, Topoisomerase I Inhibitor Payload |
||||
Robatumumab |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Robatumumab
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Rovalpituzumab (Ref) |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Rovalpituzumab (Ref)
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Sacituzumab Tirumotecan |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Sacituzumab Tirumotecan
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Seribantumab |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Seribantumab
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Sevabertinib |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Sevabertinib
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Tarextumab |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Tarextumab
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Teplizumab (Onc Adjacent) |
Investigational Monoclonal / ADC Agent | Solid Tumour | ||
|
Molecule
Teplizumab (Onc Adjacent)
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
||||
Nogapendekin Alfa InbakiceptTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
OtlertuzumabTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
PetosemtamabTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
Pinatuzumab VedotinTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
Raludotatug DeruxtecanTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Anti-CDH6 ADC, Topoisomerase I Inhibitor Payload |
|
RobatumumabTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
Rovalpituzumab (Ref)Targeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
Sacituzumab TirumotecanTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
SeribantumabTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
SevabertinibTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
TarextumabTargeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|
Teplizumab (Onc Adjacent)Targeted Therapy (Investigational Antibody / ADC) |
|
|
Therapeutic Category
Targeted Therapy (Investigational Antibody / ADC)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Investigational Monoclonal / ADC Agent |
|